Skip to main content
. 2021 Jan 4;8(4):2002228. doi: 10.1002/advs.202002228

Figure 6.

Figure 6

Platelet deletion or ICAM‐1 inhibition suppresses tumor growth and metastasis after insufficient RFA. An orthotopic HCC mouse model is established, and insufficient RFA is performed. A,B) Mice are treated with PBS, C301 (isotype control of R300), R300 (platelet deletion), and anti‐ICAM‐1 antibody (blocking ICAM‐1). Tumor volume is evaluated six weeks after insufficient RFA (n = 7, *p < 0.05, **p < 0.01, ***p < 0.001 by one‐way ANOVA). C,D) Lung metastases are examined in mice treated with PBS, C301, R300, and anti‐ICAM‐1 antibody by H&E staining (n = 7, *p < 0.05, ***p < 0.001 by one‐way ANOVA). E) An ectopic tumor model is established using wide‐type mice and ICAM‐1−/− mice, and insufficient RFA is performed. After two weeks, mice are intravenously injected with tetramelthyrhodamine‐dextran, and a multi photon‐microscope is used to observe in vivo vascular permeability. Quantification of relative fluorescence in wild‐type mice and ICAM‐1−/− mice (n = 5, **p < 0.01 by unpaired t‐test). F) Representative images of tumor vascular permeability. White arrows represent leakage of dextran from the vessels. Scale bar = 100 µm. All results are expressed as means ± SEM.